

Provided by:



Lymphoma Tumor Board and Case Conference 2025-2026

Lymphoma Tumor Board and Case Conference 2025-2026 - 6/17/2025

June 17, 2025

4:00 PM - 5:00 PM

<https://pennmedicine.zoom.us/j/99144157578>

Target Audience

This program has been designed for DERMATOLOGY, INTERNAL MEDICINE - Hematology, NUCLEAR MEDICINE, INTERNAL MEDICINE - Medical Oncology, DERMATOLOGY - Dermatopathology, CLINICAL CYTOGENETICS AND GENOMICS, CLINICAL MOLECULAR GENETICS AND GENOMICS, LABORATORY GENETICS AND GENOMICS, MEDICAL GENETICS AND GENOMICS - Molecular Genetic Pathology, PATHOLOGY - Dermatopathology, PATHOLOGY - Hematopathology

Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Discuss additional treatment options for lymphoma patients, including those that are not standard of care.
- 2 Describe clinical trials inside and outside of Penn, for which patients may be eligible
- 2 Discuss some of the complexities surrounding specific cases of diagnosing or classifying lymphoma sub-type
- 3 Discuss ongoing standard of care options of lymphoma subtypes
- 5 Discuss multi-disciplinary treatment modalities

Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physicians: Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is for **1.00** contact hours.

Pharmacists: This activity is approved for **1.00** contact hours
UAN Number: JA0000324-0000-25-015-L04-P

PAs: Penn Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.

This activity is designated for **1.00** AAPA Category 1 CME credit(s). PAs should only claim credit commensurate with the extent of their participation.

Approved for (PSRM) patient safety/risk management designation

For more information, please contact
Tamieshia Nixon
(215) 662-4074

Tamieshia.Nixon@pennmedicine.upenn.edu

Check your transcript online at <https://upenn.cloud-cme.com>

Acknowledgement of Commercial Support*

None

Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships (RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based, are based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant, and applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
John Plastaras, MD	Other Planning Committee Member	Nothing to disclose - 06/06/2025
Dale M Frank	Other Planning Committee Member	Nothing to disclose - 06/09/2025
Arthur M Feldman, MD	Other Planning Committee Member	Nothing to disclose - 04/17/2025
Sunita D. Nasta, MD	Other Planning Committee Member	Grant or research support- Genentech Consulting Fee-ADCT (Relationship has ended) Grant or research support-ONO pharmaceuticals Consulting Fee-Genmab Grant or research support-ATARA Grant or research support-Cairbou Biosciences Grant or research support-ASTEX Grant or research support-Takeda Pharmaceuticals Grant or research support-AbbVie, Inc. Membership on Advisory Committees or Review Panels, Board Membership, etc.-Merck & Co - 02/11/2025
John Kosteva, MD	Other Planning Committee Member	Nothing to disclose - 06/03/2025
David Henry, MD	Other Planning Committee Member	Nothing to disclose - 10/30/2024
Daniel Landsburg, MD	Other Planning Committee Member	Honoraria-Novartis (Advanced Health Media) (Relationship has ended) Grant or research support-ADCT Consulting Fee-AbbVie, Inc. (Relationship has ended) Membership on

		Advisory Committees or Review Panels, Board Membership, etc.-Ipsen (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Gilead Sciences, Inc (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novartis (Advanced Health Media) (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-ADCT (Relationship has ended) Speakers Bureau-ADCT Speakers Bureau-Novartis (Advanced Health Media) - 06/03/2025
Mitchell Hughes, RPH	Pharmacy Planner	Nothing to disclose - 06/03/2025
Ellen Napier, CRNP	Other Planning Committee Member	Other: travel support-Genentech Other: travel to investigator's meeting-Genmab (Relationship has ended) - 06/10/2025
Michael LaRiviere, MD	Other Planning Committee Member	Grant or research support-Merck & Co - 11/19/2024
Danielle Land, CRNP	Other Planning Committee Member	Speakers Bureau-Astra Zeneca Pharmaceuticals Membership on Advisory Committees or Review Panels, Board Membership, etc.-Incyte Corporation (Relationship has ended) Speakers Bureau-Janssen Pharmaceuticals (J&J) (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Janssen Pharmaceuticals (J&J) (Relationship has ended) - 08/18/2024
Gabriel C Caponetti, MD	Other Planning Committee Member	Paid consultant-PathAI Paid consultant-Onvivo - 06/10/2025
Siddharth Bhattacharyya, MD	Other Planning Committee Member	Nothing to disclose - 06/03/2025
Stephen J. Schuster, MD	Other Planning Committee Member	Consulting Fee-Genentech Consulting Fee-AstraZeneca Consulting Fee-BeiGene (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Caribou Biosciences Grant or research support-Genentech Grant or research support-Genentech Consulting Fee-Genmab Consulting Fee-Janssen Pharmaceuticals (J&J) Consulting Fee-Kite Pharma Consulting Fee-Novartis / Amgen Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novartis / Amgen Membership on Advisory Committees or Review Panels, Board Membership, etc.-Legend Biotech Membership on Advisory Committees or Review Panels, Board

		Membership, etc.-Nordic Nanovector (Relationship has ended) Consulting Fee-BioNTech Consulting Fee-AbbVie Advisor-Vittoria Bio - 11/15/2024
Adam Bagg, MD	Other Planning Committee Member	Consulting Fee-Scopio Speakers Bureau-Recordati - 06/03/2025
Elise Chong, MD	Other Planning Committee Member	Consulting Fee-Beigene (Relationship has ended) Consulting Fee-Astra Zeneca Pharmaceuticals (Relationship has ended) Grant or research support-AbbVie, Inc. Grant or research support-Genentech (Relationship has ended) Consulting Fee-Genentech (Relationship has ended) Grant or research support-CARGO Grant or research support-Genmab Consulting Fee-Genmab (Relationship has ended) Grant or research support-Nurix Grant or research support-Astra Zeneca Pharmaceuticals - 06/04/2025
Stefan K Barta, MD	Other Planning Committee Member	Consulting Fee-Affimed (Relationship has ended) Advisor-Bristol-Myers Squibb (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Janssen Pharmaceuticals (J&J) Consulting Fee-Seattle Genetics (Relationship has ended) Honoraria-Acrotech Consulting Fee-Daiichi Sankyo (Relationship has ended) Honoraria-Kyowa Kirin Advisor-SecuraBio (Relationship has ended) Advisor-Citius (Relationship has ended) Advisor-ONO Therapeutics (Relationship has ended) - 06/03/2025
Jakub Svoboda, MD	Co-Director	Grant or research support-Incyte Corporation Consulting Fee-Incyte Corporation (Relationship has ended) Grant or research support-Merck & Co (Relationship has ended) Grant or research support-Pharmacyclics (Relationship has ended) Consulting Fee-Bristol-Myers Squibb (Relationship has ended) Grant or research support-Bristol-Myers Squibb Grant or research support-TG Therapeutics (Relationship has ended) Consulting Fee-Seattle Genetics (Relationship has ended) Grant or research support-Seattle Genetics (Relationship has ended) Consulting Fee-Astra Zeneca Pharmaceuticals Grant or research support-Astra Zeneca Pharmaceuticals Consulting Fee-Atara Consulting Fee-Adaptive Grant or research support-Adaptive (Relationship has ended) Grant or research support-Gilead Sciences, Inc Consulting Fee-Genmab (Relationship has ended) Consulting Fee-AbbVie, Inc. Consulting Fee-CRISPR (Relationship has ended) - 11/14/2024

Rachel Lundberg, PA-C	Co-Director	Nothing to disclose - 06/12/2025
Jordan Carter, MD	Other Planning Committee Member	Honoraria-Ipsen (Relationship has ended) - 11/26/2024
Shivani Bakhshi, DO	Other Planning Committee Member	Nothing to disclose - 12/17/2024
Colin Thomas, MD	Faculty	Membership on Advisory Committees or Review Panels, Board Membership, etc.- Acrotech (Relationship has ended) Consulting Fee-Electra Therapeutics Honoraria-Olson Group Honoraria-Reckner - 06/13/2025
Abdullateef Abdulkareem, MD	Other Planning Committee Member	Nothing to disclose - 05/06/2025

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected